The U.S intranasal drug delivery devices market size surpassed USD 520 million in 2025 and is predicted to reach around USD 1361.06 million by 2035, registering a CAGR of 10.1% from 2026 to 2035. Due to increasing cases of chronic disease like migraine and allergies, rising demand for self-administration therapies and a strong adoption of painless, fast-acting and convenient drug delivery options.

U.S. Intranasal Drug Delivery Devices Market Statical Scope

It is witnessing significant technological advancement to arriving by smart nasal spray and precision drug delivery mechanisms. Innovations in formulation science such as nano-emulsions and nanoparticle-based carriers are improving bioavailability and targeting efficiency, especially for CNS disorders. Additionally, needle-free devices enhance patient comfort and compliance. Integration of digital monitoring and a 3D printed customized nuzzle device further supports accurate dosing and personalized therapy approaches in modern healthcare.

U.S. Intranasal Drug Delivery Devices Market, By System, 2025 (%)

• Metered Dose - The segment dominated the market with a 45.00% share, due to their accurate dosing, ease of use, improved patient adherence, and reliable, consistent drug administration outcomes.
• Multi-Dose Systems - The segment accounted for 35.00% of the total market share, due to their cost effectiveness, convenience for chronic therapy, an ability to provide repeated, easy dosing.
• Unit-Dose Systems - The segment accounted for 20.00% of the total market share, because they offer single use convenience, reduce contamination risk, ensure precise dosing, and are preferred for emergency and acute treatment applications.

U.S. Intranasal Drug Delivery Devices Market, By Container, 2025 (%)

• Non-Pressurized Containers - The segment dominated the market with a 55.00% share, due to their simple design, lower cost, easy handling, and suitability for wide range of nasal formulations.
• Pressurized Containers - The segment accounted for 45.00% of the total market share, because they enable precise spray delivery, consistent dosing, improved drug dispersion, and better patient experience, especially in chronic and emergency therapies.

U.S. Intranasal Drug Delivery Devices Market, By Application, 2025 (%)

• Chronic Obstructive Pulmonary Disease (COPD) - The segment accounted for 18.00% of the total market share, due to rising smoking- related cases, ageing population, and growing preference for quick, non-invasive respiratory drug administration methods.
• Rhinitis - The segment dominated the market with a 23.00% share, because allergies are highly common, affecting millions, and intranasal device provides fast, targeted, and effective symptoms relief with easy self-administration.
• Cystic Fibrosis - The segment accounted for 8.00% of the total market share, because it manage-respiratory symptoms, improves mucus clearance, and supports targeted therapy, though the patient population remain relatively limited.

U.S. Intranasal Drug Delivery Devices Market, By End User, 2025 (%)

• Ambulatory Surgical Centres - The segment accounted for 20.00% of the total market share, due to rising outpatient procedures, cost effective care delivery, and increased use of fast acting, non-invasive intranasal drug administration methods.
• Clinics - The segment accounted for 30.00% of the total market share, due to high patient visits, a strong use of intranasal therapies for common conditions, end preference for quick, efficient and non-invasive treatments.
• Hospitals - The segment dominated the market with a 40.00% share, due to high patient admissions, advanced infrastructure, and strong use of intranasal devices of emergency, acute, and a specialised treatment applications.

Top Companies in the U.S. Intranasal Drug Delivery Devices Market

• Johnson & Johnson, Inc.
• Aptar Pharma Group
• GlaxoSmithKline Plc
• Aegis Therapeutics LLC
• H&T Presspart Manufacturing Ltd.
• AstraZeneca Plc
• Becton, Dickinson and Company
• Novartis AG
• Teleflex Incorporated
• Vectura Group Plc.

Segments Covered in the Report

By System

• Metered Dose
• Multi-Dose Systems
• Unit-Dose Systems

By Container

• Non-Pressurized Containers
• Pressurized Containers

By Application

• Rhinitis
• COPD (Chronic Obstructive Pulmonary Disease)
• Asthma
• Cystic Fibrosis
• Nasal Congestion
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centres
• Others